We are live on ! Find out more
QNCX icon

Quince Therapeutics
QNCX

50 hedge funds and large institutions have $594M invested in Quince Therapeutics in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

420% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 5

367% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 3

310% more capital invested

Capital invested by funds: $145M → $594M (+$449M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

28% more funds holding

Funds holding: 39 → 50 (+11)

0.09% more ownership

Funds ownership: 0.11% → 0.2% (+0.09%)

Holders
50
Holders Change
+11
Holders Change %
+28.21%
% of All Funds
0.99%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
14
Increased
26
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$13M
2
Capital World Investors
Capital World Investors
California
+$9.47M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$5.38M
4
State Street
State Street
Massachusetts
+$3.78M
5
MWNA
Marshall Wace North America
New York
+$3.12M

Top Sellers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
-$3.71M
2
EC
EcoR1 Capital
California
-$1.25M
3
OAM
Oxford Asset Management
United Kingdom
-$591K
4
Millennium Management
Millennium Management
New York
-$529K
5
Citadel Advisors
Citadel Advisors
Florida
-$157K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Natixis
France
$674K -$18.1K -3 -5%
JP Morgan Chase
27
JP Morgan Chase
New York
$673K +$265K +44 +275%
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$622K +$332K +55 New
VEA
29
Virtus ETF Advisers
New York
$592K +$320K +53 New
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$578K +$223K +37 +247%
Fidelity Investments
31
Fidelity Investments
Massachusetts
$497K – – –
BC
32
Burleson & Co
California
$470K +$247K +41 New
Goldman Sachs
33
Goldman Sachs
New York
$443K -$6.03K -1 -3%
AIG
34
American International Group
New York
$400K +$163K +27 +300%
OAM
35
Oxford Asset Management
United Kingdom
$398K -$591K -98 -74%
Citadel Advisors
36
Citadel Advisors
Florida
$360K -$157K -26 -45%
VOYA Investment Management
37
VOYA Investment Management
Georgia
$311K +$169K +28 New
MIM
38
MetLife Investment Management
New Jersey
$300K +$163K +27 New
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$247K +$133K +22 New
Deutsche Bank
40
Deutsche Bank
Germany
$234K +$103K +17 +425%
Bank of America
41
Bank of America
North Carolina
$224K +$72.4K +12 +150%
MLICM
42
Metropolitan Life Insurance Company (MetLife)
New York
$214K +$115K +19 New
ACA
43
Atlas Capital Advisors
Wyoming
$168K +$42.2K +7 +88%
Legal & General Group
44
Legal & General Group
United Kingdom
$131K +$60.3K +10 +500%
Citigroup
45
Citigroup
New York
$130K +$66.4K +11 +1,100%
Bank of Montreal
46
Bank of Montreal
Ontario, Canada
$93K +$48.3K +8 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$87.1K +$36.2K +6 +300%
AI
48
ArchPoint Investors
Florida
$86K +$48.3K +8 New
AIP
49
Ameritas Investment Partners
Nebraska
$55K +$24.1K +4 +400%
SO
50
STRS Ohio
Ohio
$44K – – –
1
2
3

QNCX Hedge Fund Activity: Q4 2019 in Review

50 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q4 2019, worth a combined $594M — up 310% from $145M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new QNCX positions and 3 closed out — a net gain of 11 holders — while 26 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $13M. The largest seller was Alphabet Inc, cutting an estimated $3.71M.

  • 50 institutional investors held Quince Therapeutics (QNCX) as of Q4 2019, up from 39 in Q3 2019.
  • Funds reported $594M of Quince Therapeutics stock for Q4 2019, up 310% quarter-over-quarter.
  • 14 funds opened new Quince Therapeutics positions in Q4 2019 and 3 closed out, a net change of +11 holders.
  • The largest Quince Therapeutics buyer in Q4 2019 was BlackRock, an estimated $13M added.
  • The largest Quince Therapeutics seller in Q4 2019 was Alphabet Inc, an estimated $3.71M sold.

Based on aggregated 13F filings for Q4 2019.